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background: Preimplantation genetic screening (PGS) has been used in an attempt to determine embryonic aneuploidy. Techniques
that use new molecular methods to determine the karyotype of an embryo are expanding the scope of PGS.
methods: We introduce a new method for PGS, termed ‘parental support’, which leverages microarray measurements from parental
DNA to ‘clean’ single-cell microarray measurements on embryonic cells and explicitly computes conﬁdence in each copy number call. The
method distinguishes mitotic and meiotic copy errors and determines parental source of aneuploidy.
results: Validation with 459 single cells of known karyotype indicated that per-cell false-positive and false-negative rates are roughly
equivalent to the ‘gold standard’ metaphase karyotype. The majority of the cells were run in parallel with a clinical commercial PGS
service. Computed conﬁdences were conservative and roughly concordant with accuracy. To examine ploidy in human embryos, the
method was then applied to 26 disaggregated, cryopreserved, cleavage-stage embryos for a total of 134 single blastomeres. Only 23.1%
of the embryos were euploid, though 46.2% of embryos were mosaic euploid. Mosaicism affected 57.7% of the embryos. Counts of
mitotic and meiotic errors were roughly equivalent. Maternal meiotic trisomy predominated over paternal trisomy, and maternal meiotic
trisomies were negatively predictive of mosaic euploid embryos.
conclusions: We have performed a major preclinical validation of a new method for PGS and found that the technology performs
approximately as well as a metaphase karyotype. We also directly measured the mechanism of aneuploidy in cleavage-stage human embryos
and found high rates and distinct patterns of mitotic and meiotic aneuploidy.
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Introduction
Roughly 138 198 in vitro fertilization (IVF) cycles were performed in the
USA in 2006 (Centers for Disease Control and Prevention, 2008).
Unfortunately, 31% of embryos that are transferred to the uterus
during IVF survive to live birth (Centers for Disease Control and Pre-
vention, 2008). Therefore, in each IVF cycle, it is critical to make a
well-informed decision regarding which embryo(s) to transfer
(Sermon et al., 2004; Thornhill et al., 2005; Verlinsky et al., 2005).
Embryo transfer choices are frequently made by examining gross
morphological features. Though there is evidence to support the cor-
relation between morphology and implantation rates (Hardarson
et al., 2001; Borini et al., 2005; Nomura et al., 2007), recent studies
report that 30–40% of morphologically normal embryos have chro-
mosomal abnormalities such as aneuploidy (Munne ´, 2003; Baltaci
et al., 2006). Transfer of aneuploid embryos leads to universally unde-
sired outcomes such as failed embryo implantation (Munne ´ et al.,
2003), miscarriage (Warburton et al., 1986; Munne ´ et al., 1998;
Sarosi et al., 1998; Vidal et al., 1998; Pellicer et al., 1999) or birth of
trisomic offspring (Kuliev et al., 2003).
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tation genetic screening (PGS) in hopes of increasing the probability
that they will select embryos with the best chances for implantation
and development into a healthy child (Delhanty et al., 1993; Munne ´
et al., 1993; Colls et al., 2007). In the process of PGS, single cells (blas-
tomeres) are often biopsied from cultured embryos on Day 3 and ana-
lyzed for chromosome copy numbers. Embryos diagnosed as normal
(euploid) on the basis of the single- or double-cell diagnosis are
then considered for transfer into the uterus, typically between Days
4 and 6. Currently, the majority of PGS uses ﬂuorescent in situ hybrid-
ization (FISH), which typically tests 12 or fewer chromosomes in 24 h
(Delhanty et al., 1993; Munne ´ et al., 1993; Staessen et al., 2004, 2008;
Mastenbroek et al., 2007; Hardarson et al., 2008; Meyer et al., 2008;
Debrock et al., 2009). A number of studies suggest the positive effect
of PGS on clinical outcomes, with an increase implantation rates
(Munne ´ et al., 2003; Wilton et al., 2003), lower miscarriage rates (Gia-
naroli et al., 1999) and increased live birth rates (Verlinsky et al.,
2005). However, an overwhelming number of recent, randomized,
controlled clinical studies have suggested that PGS with FISH does
not improve implantation rates or live birth rates (Staessen et al.,
2004, 2008; Mastenbroek et al., 2007; Hardarson et al., 2008;
Meyer et al., 2008; Debrock et al., 2009).
However, all prior clinical trials using PGS for IVF have used FISH,
which screens for a minority of chromosomes. The limitations of
the FISH technology could have compromised the results of these
studies. Recent advances in molecular technology, such as compara-
tive genomic hybridization (CGH) and DNA microarrays, have
increased the scope of PGS (Voullaire et al., 2000; Wells and
Delhanty, 2000; Wilton et al., 2003; Hu et al., 2004; Le Caignec
et al., 2006; Sher et al., 2007; Hellani et al., 2008; Handyside et al.,
2009; Vanneste et al., 2009; Wells et al., 2008). One challenge of
molecular technology for PGS is that the ampliﬁcation of DNA from
a single cell can result in errors. This is because single-cell measure-
ments suffer from allele dropout (ADO), or the random loss of
alleles that can result in ambiguous copy number calls, and also
suffer from over-ampliﬁcation and under-ampliﬁcation of certain loci
or entire chromosomes (Walsh et al., 1992; Findlay et al., 1995;
Piyamongkol et al., 2003; Handyside et al., 2004; Renwick et al.,
2006; Spits et al., 2006; Glentis et al., 2009).
As a result of the measurement noise caused by whole-genome
ampliﬁcation, we have found that standard commercial software
packages (i.e. Illumina BeadStudio) underperform when calling copy
numberonsingle-celldata (SupplementaryMaterial,Fig.S1).Therefore,
we developed a novel method that ‘cleans’ the error-prone single-cell
microarray data using parental genetic information. The key insight of
the algorithm, termed ‘parental support’ (PS), is that copy number
determination in embryonic DNA is enhanced if supplemented with
parental genetic data because all embryonic chromosomes are
derived from parental chromosomes (Rabinowitz et al., 2007; Johnson
et al., 2008; Rabinowitz et al., 2008). The method allows IVF physicians
to screen a single cleavage-stage blastomere for chromosome copy
number across all 24 chromosomes, delivering results in time to
inform decisions on Day 5 regarding embryo transfer to the uterus.
No major preclinical validation studies have been performed for any
PGS method, including FISH. Here, we describe a major preclinical
validation of the new PS microarray method on 459 cells with
known karyotype. The data demonstrate that the preclinical accuracy
of the PS microarray method is roughly consistent with the ‘gold stan-
dard’ traditional metaphase karyotyping. We also applied the technol-
ogy to determine chromosome copy number on 134
single-blastomeres derived from 26 cryopreserved embryos from six
unrelated couples. In this cohort of embryos, we found high rates
and distinct patterns of mitotic and meiotic aneuploidy, as well as a
high rate of segmental chromosome imbalances.
Materials and Methods
Single-cell isolation, DNA ampliﬁcation
and genotyping
Single cells were isolated from buccal swabs, semen samples, adult blood,
immortalized cell lines and Day 3 cryopreserved embryos. Single-tissue
culture (lymphocytes) and buccal cells were isolated using a sterile stripper
tip (Midatlantic Diagnostic, Mt Laurel, NJ, USA) afﬁxed to a pipette
(Drummond Scientiﬁc, Broomall, PA, USA) and a stereoscope (Leica,
Wetzlar, Germany). Embryos were thawed, and then individual blasto-
meres were separated using a micromanipulator (Transferman
NK2-Eppendorf, Westbury, NY, USA) after zona pellucida drilling using
acidiﬁed Tyrode’s solution. Sperm cells were manually isolated using a
micromanipulator (Transferman NK2-Eppendorf). Aside from sperm,
single cells were washed sequentially four times with wash buffer
(5.6 mg/ml KCl, 6 mg/ml bovine serum albumin). Two different lysis/
ampliﬁcation protocols were used in the analysis: (i) Rubicon whole-
genome ampliﬁcation (Ann Arbor, MI, USA) and (ii) multiple displacement
ampliﬁcation (MDA) with proteinase K buffer (PKB). Protocol (i) was per-
formed according to the manufacturer’s instructions. For protocol (ii), cells
were placed in 5-ml PKB (Arcturus PicoPure Lysis Buffer, 50 mM DTT),
incubated at 568C for 1 h and then heat-inactivated at 958C for 10 min.
MDA reactions were incubated at 308C for 2.5 h and then 658C for
5 min. Genomic DNA from bulk tissue (Epicentre MasterAmp Buccal
Swabs, Madison, WI, USA) was isolated using the DNeasy Blood and
Tissue Kit (Qiagen, Hilden, Germany). No template controls (buffer
blanks) were performed for each ampliﬁcation method. All buffer blanks
produced intensities equivalent to the noise ﬂoor (an intensity of 1000
in the 95th percentile on the green detection channel).
Ampliﬁed single cells and bulk parental tissue were genotyped using the
Illumina (San Diego, CA, USA) Inﬁnium II genome-wide genotyping single-
nucleotide polymorphism (SNP) microarrays (HapMap CNV370Quad or
CytoSNP-12 chips). For bulk tissue (i.e. parent samples), the standard Inﬁ-
nium II protocol (www.illumina.com) was used and required call rates of
.99% using standard BeadStudio allele calling. All single cells were geno-
typed using a modiﬁed Inﬁnium II genotyping protocol such that the entire
protocol, from single-cell lysis through array scanning, was completed in
,24 h. The microarray protocol was performed as per the manufacturer’s
instructions, except that the duration of the ampliﬁcation and hybridization
steps was reduced to 7 and 6 h, respectively. Single-cell array measure-
ments that fell below the noise ﬂoor (an intensity of 1000 in the 95th per-
centile on the green detection channel) were removed from downstream
analysis. For the MDA and Rubicon protocols, this represented 1.6 and
1.3% of all ampliﬁcations, respectively. All microarray data have been
archived by the National Center for Biotechnology Information (www.
ncbi.nlm.nih.gov/geo/) under accession identiﬁer GSE19247.
Copy number determination and haplotype
phasing
We determined that commercial software packages (i.e. ChromoZone or
Homozygosity Detector in Illumina BeadStudio) underperform when
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methods generally use heterozygosity to determine copy number, and
high rates of ADO and preferential ampliﬁcation in single-cell measure-
ments result in unpredictable heterozygosity, regardless of chromosome
copy number (Supplementary Material, Table SI and Fig. S1). Allele
drop-in also occurs, but with much lower frequency (typically ,0.1%).
With such issues in mind, we implemented a chromosome copy
number classiﬁcation algorithm in MATLAB (MathWorks, Natick, MA,
USA) that makes use of parental genotypes and the observed distribution
of unprocessed single-cell microarray channel intensities grouped by par-
ental context (Rabinowitz et al., 2007, 2008; Johnson et al., 2008). As
an illustrative example, one can think of the ADO rate as one piece of infor-
mation contained in the channel intensity distributions. Furthermore, the
ADO rate is correlated to the chromosome copy number in the sense
that it decreases as the chromosome copy number increases. Hence, we
use ADO rates as a measure of the chromosome copy number. Though
in this example we focused on a single aspect of the microarray channel
intensity distributions (i.e. ADO rate), in our algorithm we make use of
the entire distribution. One can think of this as a ﬁner scale observation con-
taining much more information than any single statistic such as ADO rates.
Consider a generalized example where possible alleles at one locus are
A and B. If both parents have homozygous BB states, then the embryo will
never have AB or AA states (Supplementary Material, Fig. S2). In this case,
measurements on the A allele will, on average, have low intensities with a
distribution determined by background noise. Conversely, if both parents
have homozygous AA states, then the embryo will never have AB or BB
states, and measurements on the A allele will, on average, have very
high intensities with a distribution subject to the ADO rate and other
measurement noise characteristics.
Notice that this analysis is done without a priori knowledge of chromo-
some copy number. In general, the statistical behavior of each parental
context group will differ on the basis of the underlying chromosome
copy number of the embryo. These changes are predictable and based
on the additional allelic content that is contributed or missing from each
of the parents. First, let us deﬁne the ‘ABjBB’ parental context as the
set of all genetic loci for which the mother is AB and the father is BB,
and the ‘BBjAA’ parental context as the set of all genetic loci for which
the mother is BB and the father is AA. We would not expect the contexts
ABjBB and BBjAA to be statistically similar for a disomy, but we would
expect statistical similarity for a maternal trisomy (Supplementary Material,
Fig. S2). Our chromosome copy number calling algorithm is an extension
of this concept. In particular, we examine rank statistics for each parental
context and compare them against expected orderings under the various
chromosome copy number possibilities. We then examine the probability
that each parental context could have swapped rank by random chance to
determine copy number calls and calculate conﬁdences (Rabinowitz et al.,
2007, 2008).
Note that algorithmic calls of ‘trisomy’ are in fact three or more
chromosomes where there is an imbalance between the number of
chromosomes contributed from the mother and father, since the tech-
nique does not attempt to distinguish that case from trisomy. The algor-
ithm will call tetrasomy with equal contribution from both parents, so
long as the entire cell is not tetraploid, in which case the algorithm will
call the cell euploid. However, if any balanced tetrasomy contains
unmatched chromosomes from the parents, which is the more frequent
case, this tetrasomy will be detected by the component of the algorithm
that leverages phasing (Rabinowitz et al., 2007, 2008).
Many chromosome copy number errors are meiotic, and therefore will
include three unmatched haplotypes. Detection of three unmatched hap-
lotypes adds additional conﬁdence to a trisomy call. Therefore, we also
use parental information, high-conﬁdence disomic single-cell measure-
ments on children and recombination probabilities (genome.ucsc.edu) to
determine the phase of the parental chromosomes. For example, if two
neighboring loci both correspond to the ABjBB context, we observe
high A allele channel intensities in the children, and there is a low prob-
ability of crossover between these loci, we can predict that one parent
has two genetically linked loci with A alleles. A maximum likelihood esti-
mator (MLE) algorithm is then used to phase full chromosomes for all par-
ental genotype contexts. We then look for each of the possible haplotypes
in single-cell measurements to detect meiotic trisomies.
To detect segmental copy imbalances, each chromosome is divided into
ﬁve segments, and the algorithm is applied to each segment independently.
If any of the segments differ in copy number with high conﬁdence, the
chromosome is ﬂagged with a segmental chromosome imbalance. Note
that the reported copy number for chromosomes with a segmental imbal-
ance is reﬂective of the call on the majority of the chromosome, even if
part of the chromosome shows loss or gain. Thus, depending on size, seg-
mental copy imbalances may depress the overall conﬁdence of the full
chromosome call. However, conﬁdences on chromosomes with segmen-
tal imbalances may remain high if the deletion is relatively small and/or the
remainder of the chromosome is called with very high conﬁdence.
As reference against the PS algorithm, we developed a novel statistical
method in MATLAB, Probe Intensity Means (PIM), that uses the per-
chromosome means and standard deviations of normalized microarray
probe intensities to call chromosome copy number (Rabinowitz et al.,
2007). For each single-cell measurement, a training set of single-cell ampli-
ﬁcation microarray measurements was used to normalize probe intensities
across each chromosome. Then, an MLE algorithm was used to compute
the most likely chromosome state for all of the single-cell ampliﬁcation
microarray data.
Results
Accuracy of PS technology is roughly
concordant with traditional metaphase
karyotyping
Four hundred and ﬁfty-nine cells of known karyotype were analyzed
with the 24-h microarray genotyping protocol (Table I; Supplementary
Material, Tables SII and SIII). The majority of the cells were run in par-
allel with a commercial clinical PGS service. We used cells with
trisomy 21 to estimate false-negative rate, and euploid cells to esti-
mate false-positive rate. Two no-template-control replicates (buffer
blanks) were run for each ampliﬁcation protocol, and the results
were equivalent to background microarray intensities. All samples
were labeled with random identiﬁers so that laboratory technicians
were blind to the ploidy states of the cells. Results were then com-
pared with known karyotypes to determine accuracy.
Of the 330 known trisomy 21 cells, 7 were called either monosomy
21 or disomy 21, for a false-negative proportion of 2.1% (Supplemen-
tary Material, Table SII). Metaphase karyotypes of 100 trisomy 21 cells
by an independent reference laboratory indicated one cell that was
disomy 21, for a false-negative proportion of 1% (Table II). Thus,
the difference between the false-negative rate of the PS microarray
assay and the gold standard metaphase karyotype was no different
than expected by chance (x
2, P ¼ 0.77). Similarly, microarray analysis
indicated ﬁve aneuploid calls among 129 single euploid cells, for a false-
positive proportion of 3.9% (Supplementary Material, Table SIII). The
difference between the false-positive proportion of the PS microarray
assay and the gold standard metaphase karyotype of a euploid cell line
was no different than expected by chance (x
2, P ¼ 0.74). Across all
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than at least one prior report (Hu et al., 2004; x
2, P , 0.0001).
In addition to the cells of known karyotype, 29 single sperm and
were analyzed using PS (Table I; Supplementary Material, Table SIV).
The expectation for the sperm cells would be that all chromosomes
are paternal monosomies. With this assumption, we achieved an accu-
racy of 100% on the single sperm data. Fourteen of the sperm cells
were OX and 15 of the sperm cells were OY, a ratio not signiﬁcantly
different than expected by chance (x
2, P ¼ 0.84).
Next, we analyzed the same single-cell microarray data using a com-
puterized algorithm (PIM) that does not make use of parental infor-
mation (Table I; Supplementary Material, Table SV). PIM uses
relative chromosome intensities measured on ampliﬁed single cells
to determine a molecular karyotype. The method had a signiﬁcantly
higher false-negative rate than PS, with a 6.4% of trisomy 21 cells
called disomy 21 and 0% of sperm called haploid (x
2, P ¼ 0.012 and
P , 0.0001, respectively). Additionally, the false-positive rate was sig-
niﬁcantly higher using the chromosome means analysis method, with
96.1% of euploid cells called aneuploid on at least one chromosome
(x
2, P , 0.0001). Though other intensity-only methods might
perform better than PIM, the additional information supplied by par-
ental measurements signiﬁcantly improves accuracy in the present
data set.
Because the PS algorithm computes explicit conﬁdences for copy
number calls, we expect that higher error rates will occur among
groups of chromosomes that are assigned lower conﬁdences, and
vice versa. For example, the expectation is that 50% conﬁdence
would produce 1 error out of 2 measurements, 95% conﬁdence
would produce 1 error out of 20 measurements and so on. To
examine the relationship between conﬁdence and accuracy, we
sorted chromosome copy calls into eight conﬁdence ranges and
then calculated accuracy for each conﬁdence range (Table III). This
analysis shows that computed conﬁdences are generally conservative,
because accuracy exceeds conﬁdence for all conﬁdence ranges ,90%
(x
2, P , 0.05). For conﬁdences in the 90–100% range, accuracy was
not signiﬁcantly different than conﬁdence, suggesting that conﬁdences
in this range reﬂect true accuracy (x
2, P . 0.05). This ﬁnding is par-
ticularly important for measurements on single blastomeres, for
which the true karyotype is unknown and for which multiple measure-
ments are not possible.
High incidence of aneuploidy and mosaicism
in cleavage-stage embryos
Genotyping microarray measurements were made on 26 disaggre-
gated, cryopreserved, cleavage-stage embryos from 7 unrelated
couples, for a total of 134 single blastomeres and 3082 chromosomes
(Supplementary Material, Table SVI). The PS algorithm was then
applied to these measurements. The average donor age for the
cohort of embryos was 38.8, the youngest woman was 32 and the
oldest woman was 44. The average number of cells successfully biop-
sied per embryo was 5.2, and the average embryo grade was 1.5
(Grade 1 was the highest quality, Grade 4 was the lowest quality).
In general, our cohort of embryos was of high quality and from
women of advanced maternal age.
To determine the accuracy of any test, blind diagnoses are ﬁrst
made on cells with known karyotype. The proportion of cells with a
correct diagnosis is deﬁned as accuracy. Unfortunately, embryos com-
monly suffer from mosaicism (Los et al., 1998, 2004; Bielanska et al.,
2005; Baart et al., 2004, 2006; Barbash-Hazan et al., 2008; Daphnis
et al., 2008; Frumkin et al., 2008), so the underlying ploidy state of
any particular blastomere is unknown. Therefore, it is not possible
to compute accuracy on blastomere data. However, because chromo-
some conﬁdences computed by PS are indicative of the probability of
correct calls (Table III), conﬁdences can be used as a proxy to assess
the quality of the measurements. Across the molecular karyotypes of
134 blastomeres, 90.1% of the chromosomes were reported at .95%
conﬁdence, and the mean conﬁdence was 97.9% (Supplementary
Material, Table SVI). Notably, chromosomes with segmental imbal-
ances had signiﬁcantly lower conﬁdences than chromosomes
without segmental imbalances (one-sided t-test, P ¼ 0.018),
suggesting that segmental imbalances are a common cause of lower
conﬁdences in this cohort of embryos. In summary, we did not ﬁnd
a signiﬁcant difference between the mean conﬁdence proportion of
blastomeres and the various other cell types, so we conclude that
the blastomere data performed roughly equivalent to other cell types.
The majority of embryos and blastomeres were aneuploid, and
most of the embryos were mosaic (Table IV). More speciﬁcally,
47.8% of the blastomeres were euploid, 32.1% of the blastomeres
.............................................................................................................................................................................................
Table I Molecular karyotyping with microarrays and parental support
Cell type Number
cells
Parental support
errors
Parental support false
detection rate
Probe intensity
means errors
Probe intensity means false
detection rate
Aneuploid 330 7 2.1% 21* 6.4%
Euploid 129 5 3.9% 124* 96.1%
Haploid 26 0 0% 26* 100%
Performance statistics for molecular karyotype using microarray data and two analysis algorithms.
*Signiﬁcantly more errors using the probe intensity means analysis method (x
2, P , 0.05).
........................................................................................
Table II Traditional metaphase karyotyping
Cell type Total cells Total errors False detection rate
Aneuploid 100 1
# 1.0%
Euploid 100 4
# 4.0%
Performance statistics for metaphase karyotype by an independent laboratory.
#Unable to detect signiﬁcant difference in errors between microarray testing with PS
and metaphase karyotype (x
2, P . 0.05).
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20.1% of the cells were complex aneuploid (more than two
non-disomic chromosomes). We found no signiﬁcant difference
between the numbers of male (XY) and female (XX) blastomeres
(x
2, P ¼ 0.66), as expected assuming random segregation of chromo-
somes during meiosis. When the data are examined per embryo,
23.1% of embryos were euploid (all blastomeres euploid) and 46.2%
of embryos were mosaic euploid (at least one euploid blastomere;
Table V). Mosaicism was common in the embryos, with 57.7% of
embryos showing some discordance between at least two blasto-
meres. Three of the embryos (11.5%) were chaotic aneuploid, i.e.
all blastomeres were aneuploid and no two blastomeres had matching
ploidy. Segmental imbalances occurred in 11.9% of the blastomeres
and 38.5% of the embryos. Though segmental imbalances were
common among blastomeres and embryos, they were relatively rare
among chromosomes, accounting for only 0.7% of all chromosomes
measured. The difference between the per-embryo segmental imbal-
ance in our cohort and a prior report is not signiﬁcantly more than
expected by chance (Vanneste et al., 2009) (x
2, P ¼ 0.18). Finally,
euploid embryos did not have better morphology than chaotic aneu-
ploid embryos (one-sided t-test, P ¼ 0.43), suggesting that cleavage-
stage morphology does not predict underlying genetic state. This
ﬁnding corresponds to at least one prior report (Munne ´ et al.,
2004) but contradicts at least one other report (Magli et al., 2007),
suggesting the need for further research. However, our cohort of
embryos was small and of consistently high quality, so a larger
cohort with more variable embryo quality might yield different results.
Chromosome copy errors occurred on all chromosomes, highlight-
ing the utility of screening for errors on all 24 chromosomes. Though
embryos and blastomeres showed high rates of aneuploidy, most
chromosomes (83.9%) were disomic (Table VI). Monosomies were
more common than trisomies (x
2, P , 0.0001), concordant with
larger studies using FISH (Munne ´ et al., 2004; Thornhill and Handyside,
2009). All chromosomes showed at least one monosomy or trisomy
in at least one blastomere, demonstrating that no chromosome
escapes copy number errors in human cleavage-stage embryos. We
found no per-chromosome bias in copy number errors, i.e. no
chromosome had a particular propensity for aneuploidy. This contra-
dicts some prior reports that aneuploidy occurs more frequently on
certain chromosomes (Munne ´ et al., 2004, 2007). We found no
chromosomes with uniparental disomy, which is not signiﬁcantly differ-
ent than expected given a prior report (Vanneste et al., 2009; x
2, P ¼
0.42). Notably, if applied to these embryos, FISH for Chromosomes 1,
13, 16, 17, 18, 21, X and Y (e.g. Mastenbroek et al., 2007) would
have failed to detect 27.2% of all aneuploid blastomeres.
........................................................................................
Table V Embryo ploidy states
Category Proportion Embryo grade
Euploid 6/26 1.5
#
Mosaic euploid 12/26 1.9
Chaotic aneuploid 3/26 1.7
Paternal meiotic aneuploid 1/26 3
Maternal meiotic aneuploid 8/26* 2.1
Segmental error 10/26 1.4
Proportion of 26 embryos falling in various ploidy categories, and average embryo grade
within each category.
*Signiﬁcantly more maternal errors than paternal errors (x
2, P , 0.0001).
#Unable to detect signiﬁcant difference from the distribution of all embryos combined
(t-test, P . 0.05).
.............................................................................................................................................................................................
Table III Conﬁdence ranges compared with accuracy
Conﬁdence range Number chromosomes Expected errors Actual errors PS accuracy P-value
50–60% 20 9 1 95.0% 0.0084*
60–70% 37 13 4 89.2% 0.0271*
70–80% 62 15 2 96.8% 0.0017*
80–90% 142 21 6 95.8% 0.0046*
90–95% 172 13 7 95.9% 0.2493
#
95–99% 526 2 3 99.4% 1
#
99–99.9% 700 4 6 99.1% 0.751
#
99.9–100% 1638 8 9 99.5% 1
#
Computed conﬁdence ranges and accuracy for chromosome measurements using microarrays with PS.
*Signiﬁcantly better accuracy than expected from the computed conﬁdence (x
2, P , 0.05).
#Unable to detect difference between accuracy and computed conﬁdence (x
2, P . 0.05).
........................................................................................
Table IV Blastomere ploidy states
Category Proportion
Euploid 64/134
Aneuploid 43/134
Complex aneuploid 27/134
Maternal only 42/134*
Paternal only 8/134
Meiotic trisomy 19/134*
Segmental error 16/134
Proportion of 134 blastomeres falling in various ploidy categories. *Signiﬁcantly more
maternal errors than paternal errors (x
2, P , 0.0001).
1070 Johnson et al...........................................................................................................................................................................................................................................................
..........................................................................................................................................................................................................................................................
Table VI Per-chromosome blastomere copy number state
Blastomere copy number state
Disomy XX XY (2mat)mit (2pat)mit (2mat)mei (2pat)mei (1mat)mit (1pat)mit (1mat)mei X,
(2pat)mit
X,
(2mat)mit
Y XXY,
(1mat)mit
XXY,
(1mat)mei
XXX,
(1mat)mit
(2mat),
(2pat)
Segmental
imbalance
Chromosome 1 121 1 4 1 4 33
2 117 3 7 2 1 2 2
3 120 5 5 2 2 1
4 119 6 4 3 2
5 116 5 5 3 1 2 26
6 118 5 4 2 1 2 2
7 118 4 7 2 1 2 3
8 120 4 4 2 1 2 1
9 119 3 4 3 2 32
10 120 4 5 2 2 1
11 119 4 5 2 1 2 11
12 112 4 5 3 8 2
13 119 1 2 4 2 2 4
14 116 4 7 2 1 2 2
15 119 4 4 1 3 2 12
16 111 7 2 2 8 4
17 119 4 4 3 2 2
18 109 6 5 4 5 5 2
19 121 4 4 1 2 2
20 121 4 3 2 1 2 11
21 119 4 2 4 2 3
22 113 4 5 8 1 2 1
sex 69 52 11 2 2 2 2 3
Sum 2586 69
# 52
# 90 97 12* 2 51 14 61* 1 1 2 2 2 2 38 21
Number of chromosome calls falling into various copy number states. The disomy column indicates disomic chromosomes measurements, and XX and XY indicate disomic female and male measurements, respectively. The (–pat)mit and the
(–mat)mit columns indicate maternal and paternal mitotic monosomy, respectively. The Y column indicates a monosomy on the sex chromosomes. The XXY, (þmat)mit column indicates an additional mitotic X chromosome from the mother,
the XXY, (þmat)mei column indicates an additional meiotic X chromosome from the mother. The XXX, (þmat)mit column indicates maternal mitotic trisomy X. The (þmat)mit and (þpat)mit columns indicate maternal and paternal mitotic
trisomies, respectively. The (2mat)mei and (2pat)mei columns indicate maternal and paternal meiotic monosomies, respectively. The (þmat)mei column indicates maternal meiotic trisomy. The (2mat), (2pat) column indicates a null
chromosome measurement. Finally, the segmented column indicates a chromosome that showed segmental errors.
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1Additionally, if FISH for 8-chromosomes had been used, 22.9% of the
blastomeres diagnosed as ‘euploid’ would have actually been
aneuploid. Thus, clinical application of 8-chromosome FISH to our
cohort of embryos would have resulted in the transfer of some aneu-
ploid embryos.
Meiotic errors are predictive of fully
aneuploid embryos
Aneuploidies arise from mitotic or meiotic non-disjunction (Los et al.,
1998, 2004; Mantzouratou et al., 2007; Frumkin et al., 2008). Parental
source of aneuploidy can be a useful proxy for the detection of meiotic
errors, because maternal meiotic errors are expected to predominate
over paternal meiotic errors (Fragouli et al., 2006a, b; Frumkin et al.,
2008). Across the 134 blastomeres in this study, signiﬁcantly more tri-
somies (84.8%) were maternal in origin than were paternal in origin
(Table VI; x
2, P , 0.0001). This is despite the fact that there was
no signiﬁcant difference between the numbers of maternal and
paternal monosomies across the 134 blastomeres (x
2, P ¼ 0.96).
This skewed distribution suggests that most monosomies are
mitotic, whereas most trisomies are maternal meiotic.
However, better conclusions can be drawn regarding mechanism of
non-disjunction if individual monosomies and trisomies are speciﬁcally
diagnosed as mitotic or meiotic. Thus, we identiﬁed meiotic trisomies
by looking for three distinct parental haplotypes for a particular
chromosome, and meiotic monosomies by looking for monosomy
concordant in the same chromosome across all blastomeres in an
embryo. Across our data set, 30.8% of embryos harbored meiotic
aneuploidy and 14.2% of blastomeres harbored meiotic trisomies.
However, a high frequency of maternal meiotic errors alone did not
explain the dominance of maternal trisomies, as the incidences of
mitotic and meiotic trisomies were roughly equivalent (x
2, P ¼
0.99). We postulate that this unexpected result is due to the failure
of our algorithm to accurately distinguish certain meiotic errors from
mitotic errors, since the method is dependent on computational
phasing, which requires meiotic crossovers to produce highly
rearranged chromosomes. The difference between counts of maternal
and paternal meiotic monosomies was not signiﬁcantly greater than
expected by chance (x
2, P ¼ 0.59). Notably, however, signiﬁcantly
more meiotic trisomies were maternal than paternal, as zero paternal
meiotic trisomies were detected (x
2, P , 0.0001). Thus, our data set
suggests that, though mitotic and meiotic errors were both common in
this set of human cleavage-stage embryos, most meiotic trisomies
were maternal in origin.
If necessary, a clinician might consider transfer of a mosaic euploid
embryo instead of a fully aneuploid embryo. Any evidence that
suggests a fully aneuploid embryo could help inform transfer decisions.
In our study, 79.0% of blastomeres that contained meiotic trisomies
belonged to embryos that were fully aneuploid, i.e. all of the blasto-
meres in the embryo were aneuploid. In contrast, only 30.4% of blas-
tomeres that had only mitotic trisomies belonged to embryos that
were fully aneuploid. Thus, blastomeres with meiotic trisomies had
a signiﬁcantly higher probability of belonging to a fully aneuploid
embryo (x
2, P ¼ 0.005). In summary, our analysis of aneuploidy mech-
anisms demonstrates that most trisomies are maternal meiotic errors,
and that the presence of maternal meiotic errors in a single blasto-
mere is positively predictive of a fully aneuploid embryo.
Discussion
We have performed a large preclinical validation study to determine
the accuracy of a new microarray method for molecular karyotyping.
With over 200 cells measured by metaphase karyotype and 459 cells
measured by the PS microarray method, we found that the per-cell
accuracies of the methods are roughly in line. However, any validation
of a method for single-cell karyotyping suffers from possible karyotypic
mosaicism inherent to tissues. Thus, the true accuracy of both tra-
ditional metaphase karyotyping and the new microarray method
might be even higher than reported here, because many of the
‘errors’ may reﬂect accurate measurements on a mosaic population
of cells.
Conﬁdence is essentially the probability that the copy number call is
correct, i.e. a 90% conﬁdence means that 9 out of 10 calls will be
correct. Medical practitioners use the conﬁdence of a particular
chromosome call to help make informed clinical decisions, i.e. if two
blastomere measurements are euploid, but one has lower conﬁdence,
it should be preferable to transfer the embryo with higher conﬁdence.
Our preclinical validation data set on 459 cells of known karyotype
indicated that conﬁdences were conservative, with accuracy rates gen-
erally exceeding conﬁdences.
The PS microarray method also achieved high rates of accuracy on
single sperm. As shown in our separate analysis of these same data,
intensity-only algorithms necessarily make assumptions regarding the
underlying ploidy state of the cell, i.e. haploid, diploid or triploid. In
the case of sperm measurements, the proper ploidy using the mean
chromosome intensity was actually a haploid, but the PIM algorithm
was not able to distinguish this from diploid mean chromosome inten-
sity. Similar problems would presumably occur with triploid genome
measurements. Here, parental information has proven useful to over-
come this challenge.
We applied PS to a cohort of 26 early-cleavage-stage (Day 3)
embryos for initial validation and to gain a better understanding of
embryo mosaicism and aneuploidy rates when all 24 chromosomes
are tested. Our results indicate that 23.1% of embryos were euploid
and 57.7% were mosaic. Studies using FISH reported mosaicism
rates of 18.1–57% and euploidy rates of 19–36% (Bielanska et al.,
2005; Baart et al., 2004, 2007; Munne ´ et al., 2007; Barbash-Hazan
et al., 2008). Prior studies using alternative 24-chromosome screening
methods indicated whole-chromosome imbalances in at least one
blastomere in 75–83% of embryos, and mosaicism rates of 66–87%
(Wells and Delhanty, 2000; Vanneste et al., 2009). Rates of per-
embryo segmental chromosome imbalances were also not signiﬁcantly
different from prior reports (Vanneste et al., 2009; x
2, P . 0.05).
Thus, proportions of chromosome imbalances and mosaicism in our
present study are consistent with expectations based on prior data
and add to the increasing body of evidence demonstrating the
extreme karyotypic instability of human embryos generated from
oocytes collected after artiﬁcial stimulation and then cultured in vitro.
We were able to determine whether aneuploidies were meiotic or
mitotic, and the parental source of aneuploidy, without data from
polar body biopsies. These data are evidence that aneuploidies com-
monly arise due to both zygotic and meiotic non-disjunction.
However, monosomies are mostly zygotic (i.e. anaphase lag; Kalousek
et al., 1991) and trisomies are mostly maternal meiotic. In concor-
dance with our data on maternal meiotic errors, prior data suggest
1072 Johnson et al.that 12–41.8% of human oocytes are aneuploid (Kuliev et al., 2003;
Pellestor et al., 2003; Kuliev and Verlinsky, 2004; Frumkin et al.,
2008), and that 80% of children born with aneuploidy harbor
maternal trisomies (Nicolaidis and Peterson, 1998). At least one
study measured aneuploidy in polar bodies using CGH and found
that oocytes confer a higher risk of trisomy than monosomy (Keskin-
tepe et al., 2007), whereas other studies have suggested that fertilized
oocytes are equally at risk for monosomy and trisomy (Fragouli et al.,
2006a, b). Measurements should be made on larger sets of embryos in
order to further clarify the issue. Regardless, one might speculate that
ovarian stimulation is disruptive to meiosis, or that in vitro culture is
disruptive to zygotic mitosis. In the future, IVF clinicians may be able
to adjust stimulation protocols and in vitro culture conditions to
reduce the possibility of certain types of aneuploidy during IVF.
Paradoxically, high rates of aneuploidy and chromosomal imbal-
ances suggest the importance of PGS in selecting healthy embryos,
whereas mosaicism complicates the meaningfulness of the diagnosis
delivered (e.g. Vanneste et al., 2009). Thus, information that helps
to predict the ploidy state of the remainder of an embryo given single-
blastomere measurements could be a powerful addition to PGS.
There is already some evidence that mosaic euploid embryos are
more likely to ‘self-correct’ by blastocyst stage (Baart et al., 2004;
Munne ´ et al., 2005; Barbash-Hazan et al., 2008). Several mechanisms
have been proposed to explain the self-correction phenomenon such
as chromosome demolition (Los et al., 1998), anaphase-lag correction
(Kalousek et al., 1991) or non-disjunction (Tarin et al., 1992). Self-
correction of a mosaic embryo might also occur as a result of aneu-
ploid cells undergoing apoptosis and/or better proliferative capacity
of euploid cells (Lightfoot et al., 2006). We are currently conducting
studies to further examine the relationship between meiotic aneu-
ploidy at the cleavage stage and the potential to form a euploid blas-
tocyst, and may, in the future, add this information to clinical PGS
reports.
Recent, randomized, controlled studies have indicated that PGS
does not improve implantation rates or live birth rates in IVF (Staessen
et al., 2004, 2008; Mastenbroek et al., 2007; Hardarson et al., 2008;
Meyer et al., 2008; Debrock et al., 2009). This might be because
these studies used ﬁrst-generation PGS technology that does not
screen all 24 chromosomes, and therefore misses many aneuploid
blastomeres (Wilton et al., 2003; Keskintepe et al., 2007). In the
present data set, we found that 8-chromosome FISH would have
had a high false-negative rate because many blastomeres had aneuploi-
dies on chromosomes not typically tested in FISH. Therefore, it is
likely that nearly one-quarter of all ‘euploid’ embryos transferred in
prior randomized, controlled clinical studies were actually aneuploid.
Additionally, the FISH studies have unknown false-positive rates, i.e.
euploid cells might be diagnosed aneuploid due to poor technique
(Cohen and Grifo, 2007). Future studies that use more comprehensive
technology with known accuracy rates might therefore signiﬁcantly
improve both implantation rates and live birth rates.
The microarray technology described here has been used since
October 2008 in PGS clinical practice by IVF clinics for a variety of
clinical indications using both cleavage-stage and blastocyst biopsies.
Given the broad applicability of the PS microarray technology, the
method can be easily extended to other areas where DNA material
is limited, such as non-invasive prenatal diagnostics, studies on early
embryonic stem cell passages and early tumor detection.
Supplementary data
Supplementary data are available at humrep.oxfordjournals.org.
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